Amgen Inc. (AMGN)

Amgen Inc. (AMGN-Q) is seen as a well-managed and innovative biotech company that has shown impressive performance in its recent earnings reports, surpassing expectations in both revenue and profit margins. Analysts highlight a robust pipeline, with 15 of its products experiencing double-digit sales growth, which suggests strong ongoing demand for their offerings. Additionally, Amgen's work in GLP-1 drugs, including a potential game-changing product in phase 3 testing, has garnered positive sentiment, alongside its attractive dividend yield. Overall, experts suggest holding the stock for long-term gains, with a favorable outlook considering the current market trends and the company's positioning within the biotech sector.